Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end Carlsbad, CA, May 01, 2024 (GLOBE NEWSWIRE) -- Palisade...

Glasswing Ventures Raises Oversubscribed $158M Fund II BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Glasswing Ventures, an early-stage venture capital firm investing in the next generation of intelligent enterprise and frontier technology startups, today...

Immuron Granted US Patent for NASH Treatment MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...

Lender Processing Services, Inc. Acquisition by Fidelity National Financial, Inc. May Not be in the Best Interests of LPS Shareholders NEW YORK, May 29, 2013 (GLOBE NEWSWIRE) -- The fairness of the proposed acquisition of Lender Processing Services, Inc. ("LPS" or the "Company") by Fidelity National Financial, Inc. ("FNF") is the...

Potential Investors Into Private Equity Funds Feel Ill-Equipped to Evaluate PE Teams -- Even Though "People" Dimension of Managers Is Now of Greater Investor Concern Than Investing Strategy, According to New Survey Results DENVER, CO--(Marketwire - May 17, 2011) - While investors into Private Equity funds say they feel equipped to assess funds' investment strategies, they say they feel ill-equipped to assess private...